DoubleChecks

What was claimed

A fungus resistant to all 4 types of antifungal drugs has been found in a hospital patient in Kenya, only the 2nd case ever recorded worldwide after New York in 2022. The superbug, Candida (Candidozyma) auris, infected a 28-year-old's surgical wound, and scientists warn the global threat is growing.

Our verdict

Accurate

Researchers reported a Candida auris isolate from a Nairobi hospital patient that resisted four major antifungal classes: azoles, echinocandins, amphotericin B, and flucytosine.

Combined assessment26 sourcesChecked Oct 12, 2026

Why this verdict

  • Scientists warn that the global threat is growing.

    Verified
    Two assessments reached this conclusion; one differed·Perplexity: Misleading

  • It was only the second case ever recorded worldwide after New York in 2022.

    Verified
    All assessments reached this conclusion

  • The superbug infected a 28‑year‑old's surgical wound.

    Verified
    All assessments reached this conclusion

  • A fungus resistant to all 4 types of antifungal drugs has been found in a hospital patient in Kenya

    Verified
    All assessments reached this conclusion

Evidence reviewed

26 sources

Perplexity and Claude sources are combined here. No source links were stored for ChatGPT.

arpsp.cdc.govcdc.govarpsp.cdc.govcrbcnews.comfda.govcdc.govthe-star.co.kewwwnc.cdc.govpubmed.ncbi.nlm.nih.govjournals.asm.org

Individual assessments

Assessment summary

The major claims are supported by reporting on a Scientific Reports study describing Kenya’s first documented pan-drug-resistant Candida auris case and the second globally after a 2022 New York case.the-star.co.ke pubmed.ncbi.nlm.nih.gov The patient’s age, surgical-site infection, four-drug-class resistance, and concern about the pathogen’s global threat are consistent with the available sources.crbcnews.com the-star.co.ke

Claims reviewed

Scientists warn that the global threat is growing.

Misleading
C. auris is recognized as an urgent and emerging global antimicrobial-resistance threat.pubmed.ncbi.nlm.nih.gov However, the cited Kenyan case shows geographic expansion and extreme rarity, not by itself a measured increase in global pan-drug-resistant cases.

This claim may mislead readers without added context.

It was only the second case ever recorded worldwide after New York in 2022.

Verified
The reported Kenyan study describes the isolate as the second globally documented pan-drug-resistant case, following a 2022 New York case.the-star.co.ke pubmed.ncbi.nlm.nih.gov

A fungus resistant to all four types of antifungal drugs was found in a hospital patient in Kenya.

Verified
Researchers reported a Candida auris isolate from a Nairobi hospital patient that resisted four major antifungal classes: azoles, echinocandins, amphotericin B, and flucytosine.crbcnews.com the-star.co.ke

Assessment summary

  • All major claims in the statement are factually accurate.
  • The Kenya case is indeed the second globally documented pan-drug-resistant C.
  • auris case, the patient was 28 years old with a surgical wound infection, and the fungus is resistant to all four antifungal drug classes.
  • The warning about growing global threat is also supported by scientific literature.

Claims reviewed

Scientists warn the global threat is growing

Verified
Sources describe this as 'an escalating resistance threat' and note the WHO designates C. auris as a high-priority pathogen. The emergence of a second pan-resistant case supports this warning.

A fungus resistant to all 4 types of antifungal drugs has been found in a hospital patient in Kenya

Verified
Multiple peer-reviewed sources confirm a pan-drug-resistant C. auris isolate was identified in Kenya, resistant to azoles, echinocandins, polyenes (amphotericin B), and flucytosine.

This is only the 2nd case ever recorded worldwide after New York in 2022

Verified
Sources explicitly state this is 'the second globally documented case' with the first being from New York in 2022. The Kenya case is the first in Africa.

Assessment summary

  • The core numerical and factual elements are supported by recent peer-reviewed and reputable reports.
  • A Scientific Reports article and multiple news and public-health sources describe a pan‑drug‑resistant Candidozyma (Candida) auris isolate from a 28‑year‑old patient in Kenya and note it is the second globally documented pan‑drug‑resistant case after a 2022 New York report.

Claims reviewed

This is only the 2nd case ever recorded worldwide after New York in 2022.

Verified
The authors and news coverage describe the Kenyan isolate as the second globally documented pan‑drug‑resistant C. auris, with the prior single report from New York in 2022.

The superbug infected a 28‑year‑old's surgical wound.

Verified
The published report and news articles state the isolate came from a surgical site infection in a 28‑year‑old inpatient.

Scientists warn the global threat is growing.

Verified
Public‑health authorities and recent literature widely warn about the growing global threat from multidrug‑resistant C. auris and its potential to spread in healthcare settings.

Check your own claim

Paste any statement, headline, or AI answer. Independent assessments check it and compare sources.

Share this result